Core Insights - Tevogen Bio's Founder and CEO, Ryan Saadi, has been recognized in the 2025 NJBIZ Power 100 for his influence in New Jersey's business landscape [1] - The company focuses on developing affordable and accessible T cell therapies for viral infections and cancers using its proprietary ExacTcell technology [2][7] - Tevogen Bio aims to challenge high drug development costs with an efficient business model, emphasizing sustainability and patient accessibility [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes to create precision T cell therapies for infectious diseases and cancers [4] - The company has reported positive safety data from its proof-of-concept clinical trial, with key intellectual property assets wholly owned and not subject to third-party licensing [4] - Tevogen Bio's leadership believes that personalized therapeutics and innovative business models are essential for sustaining medical innovation [5] Recent Developments - A proof-of-concept trial utilizing ExacTcell technology yielded highly positive results, which have been published in Blood Advances [2][7] - The launch of Tevogen.AI and a partnership with Microsoft are significant steps towards making therapies more accessible [2][7]
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy